Basys.ai Receives Top Recognition from CMS in the Crushing Fraud, Waste, and Abuse Challenge

Basys.ai, an agentic AI-powered prior authorization and utilization management platform, has been selected by the Centers for Medicare & Medicaid Services (CMS) as a national finalist in the Crushing Fraud, Waste, and Abuse (FWA) Challenge. CMS announced the finalists during its national showcase highlighting the top innovations advancing program integrity and affordability across Medicare. The […]

EPRI Launches Global Effort to Prepare Future-Ready Grids

The aftermath of the 2025 Iberian blackout highlighted how rapidly changing grid conditions can overwhelm traditional monitoring and control processes. EPRI today announced a global initiative to modernize how the electric sector detects, anticipates, and responds to emerging risks and manages increasing complexity in an era of rapid change. The effort, Rapid Adaptation of Grid

Shulman Rogers Welcomes Kevin Lees to its Corporate and Investment Funds Practices

Shulman Rogers is pleased to announce that Kevin Lees has joined the firm as a Shareholder in the Corporate and Investment Funds practices. Kevin brings nearly twenty years of experience advising fund sponsors and institutional investors in the United States and around the world. His arrival significantly strengthens two of the firm's fastest-growing practice areas

Solidion Technology develops a new high-capacity, low-cost anode

Recently discovered anode is composed of low-cost silicon particles protected by a flexible rubber to significantly extend the range of commercial drones Solidion Technology, Inc. (Nasdaq: STI), an advanced battery technology solutions provider, today announced that it has developed a new breed of silicon-rich high-capacity anode for lithium-ion batteries. https://mma.prnewswire.com/media/2553642/Solidion_Logo.jpg Solidion has pioneered multiple approaches

BingX Celebrates Reaching 40M Users in 2025 with Beyond the Alpha Campaign

In 2025,BingX achieved 100% user growth, with a peak 24-hour trading volume surpassing $26 billion, underscoring strong global adoption and momentum. — AI-nativeCrypto Pioneer: BingX made an industry-first $300 million commitment to AI integration, positioning AI as a core growth engine. The company successfully launched two AI-powered trading tools to enhance user decision-making and trading

Emeren Group Announces Completion of Merger

Emeren Group Ltd (“Emeren” or the “Company”) (www.emeren.com) (NYSE: SOL), a leading global solar project developer, owner, and operator, today announced the completion of the merger contemplated by the previously announced agreement and plan of merger dated June 18, 2025,as amended by an amendment agreement dated September2, 2025 (the “Merger Agreement”), among the Company, Shurya

Greenwich LifeSciences Announces Preliminary Analysis Showing 80% Recurrence Rate Reduction in the Open Label Arm of FLAMINGO-01

(NASDAQ:GLSI), STAFFORD, Texas, Dec. 15, 2025 (GLOBE NEWSWIRE) — Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the “Company”), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, today announced an approximately 80% recurrence rate reduction in the open label non-HLA-A*02 arm of FLAMINGO-01.

Merriam-Webster Announces “Slop” as the 2025 Word of the Year

Springfield, MA, Dec. 15, 2025 (GLOBE NEWSWIRE) — Today Merriam-Webster announced the 2025 Word of the Year: slop. Slop is defined as “digital content of low quality that is produced usually in quantity by means of artificial intelligence.” Throughout 2025, lookup volume of slop on Merriam-Webster.com reflected a flood of slop into everyday life, including

Palvella Therapeutics Announces Positive Topline Results from Phase 2 TOIVA Clinical Trial of QTORIN(TM) 3.9% Rapamycin Anhydrous Gel (QTORIN(TM) rapamycin) for the Treatment of Cutaneous Venous Malformations, a Serious, Rare Genetic Disease with No FDA-approved Therapies

(NASDAQ:PVLA), 73% of trial participants (11/15 participants) improved on the Overall Cutaneous Venous Malformations Investigator Global Assessment (Overall cVM-IGA) at Week 12; 67% of trial participants (10/15 participants) rated as “Much Improved” (+2) or “Very Much Improved” (+3) on the Overall cVM-IGA at Week 12 Achieved statistical significance on multiple pre-specified clinician-reported and patient-reported efficacy

Scroll to Top